A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azac

I'm Interested!

Please call
1-800-641-2422

Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia

Sex at Birth: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Leukemia

Study Purpose

This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.

Principal Investigator
Brenda Cooper MD

Department/Division
Cancer (Leukemia)

Locations

UH Seidman Cancer Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: 23-939, STUDY20240069
StudyID: KURA1923
ClinicalTrials.gov: NCT05735184

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422